Clinical efficacy of intravesical gemcitabine combined with ubenimex in patients with non-muscle-invasive bladder carcinoma after transurethral resection of bladder tumor

被引:1
作者
Shao, Li-Jun [2 ]
Wang, Hai-Jiang [2 ]
Wang, Jia-Rong [1 ]
Yuan, Xiao-Fei [2 ]
Sha, Quan [2 ]
机构
[1] Baoding Childrens Hosp, Dept Oncol, Baoding 071051, Hebei, Peoples R China
[2] Baoding 1 Hosp, Dept Urol, Baoding 071000, Hebei, Peoples R China
关键词
Gemcitabine; Immunotherapy; Urothelial carcinoma of the bladder; Non-muscle-invasive; Transurethral resection of bladder tumor; CANCER; RECURRENCE; MULTICENTER; PROGRESSION; DOCETAXEL; DIAGNOSIS; THERAPY; FAILURE; CELLS;
D O I
10.12669/pjms.38.5.4599
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: To evaluate the clinical value of intravesical gemcitabine combined with immunotherapy in patients with non-muscle-invasive bladder carcinoma (NMIBC) after transurethral resection of bladder tumor (TURBT). Methods: Eighty patients with non-muscle-invasive urothelial carcinoma treated in Baoding No.1 Hospital from November 2016 to November 2019 were randomly divided into two groups, with 40 patients in each group. Both groups underwent TURBT. After surgery, the research group was treated with intravesical chemotherapy using gemcitabine combined with ubenimex, while the control group was given 40 mg pirarubicin by intravesical instillation. Postoperative condition was evaluated by cystoscopy every three months in both groups. The recurrence six months, one year and two years after treatment, the incidence of lower urinary tract symptoms such as dysuria, hematuria and frequent urination, general adverse drug reactions such as rashes, liver function damage and gastrointestinal reaction, as well as the changes in CD3(+), CD4(+), CD8(+) and CD4(+)/CD8(+) T lymphocyte subsets before and after treatment were comparatively analyzed between the two groups. Results: The recurrence rate showed no statistical significance between the two groups 6 months after treatment (p=0.17), but significant differences one year (p=0.04) and two years (p=0.03) after treatment, which were significantly lower in the research group than the control group. The incidence of adverse drug reactions was 22.5% in the research group and 7.5% in the control group, without significant difference (p=0.36). The incidence of lower urinary tract symptoms was 32.5% and 55%, respectively, in the research group and the control group. The incidence of lower urinary tract symptoms in the research group was significantly lower compared with the control group, with a statistically significant difference (p=0.04). After treatment, CD3(+), CD4(+) and CD4(+)/CD8(+) levels in the research group increased significantly than those in the control group, with statistically significant differences (CD3(+), p=0.01; CD4(+), p=0.00; CD4(+)/CD8(+), p=0.00). Conclusions: For NMIBC patients receiving bladder-preserving surgery, intravesical gemcitabine combined with immunotherapy can reduce the recurrence rate, relieve lower urinary tract symptoms, increase the tolerance of patients to intravesical chemotherapy and significantly improve the function of T lymphocytes, without obvious increase in adverse drug reactions. Therefore, it is safe and effective, and has certain clinical value.
引用
收藏
页码:1243 / 1249
页数:7
相关论文
共 30 条
  • [1] Can the neutrophil-to-lymphocyte ratio be used to predict recurrence and progression of non-muscle-invasive bladder cancer?
    Albayrak, Sebahattin
    Zengin, Kursad
    Tanik, Serhat
    Atar, Muhittin
    Unal, Serhat Haluk
    Imamoglu, M. Abdurrahim
    Gurdal, Mesut
    [J]. KAOHSIUNG JOURNAL OF MEDICAL SCIENCES, 2016, 32 (06) : 327 - 333
  • [2] Current treatments for BCG failure in non-muscle invasive bladder cancer (NMIBC)
    Alvarez-Maestro, M.
    Guerrero-Ramos, F.
    Rodriguez-Faba, O.
    Dominguez-Escrig, J. L.
    Fernandez-Gomez, J. M.
    [J]. ACTAS UROLOGICAS ESPANOLAS, 2021, 45 (02): : 93 - 102
  • [3] Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends
    Antoni, Sebastien
    Ferlay, Jacques
    Soerjomataram, Isabelle
    Znaor, Ariana
    Jemal, Ahmedin
    Bray, Freddie
    [J]. EUROPEAN UROLOGY, 2017, 71 (01) : 96 - 108
  • [4] En bloc transurethral resection with 2-micron continuous-wave laser for primary non-muscle-invasive bladder cancer: a randomized controlled trial
    Chen, Xu
    Liao, Jun
    Chen, Lingwu
    Qiu, Shaopeng
    Mo, Chengqiang
    Mao, Xiaopeng
    Yang, Yuanzhong
    Zhou, Shiying
    Chen, Junxing
    [J]. WORLD JOURNAL OF UROLOGY, 2015, 33 (07) : 989 - 995
  • [5] Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018
    Cumberbatch, Marcus George Kwesi
    Jubber, Ibrahim
    Black, Peter C.
    Esperto, Francesco
    Figueroa, Jonine D.
    Kamat, Ashish M.
    Kiemeney, Lambertus
    Lotan, Yair
    Pang, Karl
    Silverman, Debra T.
    Znaor, Ariana
    Catto, James W. F.
    [J]. EUROPEAN UROLOGY, 2018, 74 (06) : 784 - 795
  • [6] DeGeorge KC, 2017, AM FAM PHYSICIAN, V96, P507
  • [7] Gemcitabine Versus Bacille Calmette-Guerin After Initial Bacille Calmette-Guerin Failure in Non-Muscle-Invasive Bladder Cancer A Multicenter Prospective Randomized Trial
    Di Lorenzo, Giuseppe
    Perdona, Sisto
    Damiano, Rocco
    Faiella, Adriana
    Cantiello, Francesco
    Pignata, Sandro
    Ascierto, Paolo
    Simeone, Ester
    De Sio, Marco
    Autorino, Riccardo
    [J]. CANCER, 2010, 116 (08) : 1893 - 1900
  • [8] Farling KB, 2017, NURSE PRACT, V42, P26, DOI 10.1097/01.NPR.0000512251.61454.5c
  • [9] Ubenimex Reverses MDR in Gastric Cancer Cells by Activating Caspase-3-Mediated Apoptosis and Suppressing the Expression of Membrane Transport Proteins
    Guo, Qie
    Jing, Fan-jing
    Qu, Hai-jun
    Xu, Wen
    Han, Bing
    Xing, Xiao-min
    Ji, Hong-yan
    Jing, Fan-Bo
    [J]. BIOMED RESEARCH INTERNATIONAL, 2019, 2019
  • [10] Efficacy of Standardised Treatments Combined with Ubenimex in Patients with Malignant Tumors
    Hu, Xin
    Xiong, Haofeng
    Huang, Shiying
    Mao, Ting
    Yang, Liudi
    Su, Tong
    [J]. JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2021, 31 (02): : 206 - 209